

A Message from the Co-Chairs

Welcome to another edition of the ROADMAP Newsletter.

We continue to build strong momentum, with new sites coming on board across Australia and New Zealand, and Canadian sites expected to activate soon. **We now have 24 sites active in Australia (up from 11 in the previous newsletter) and 3 in New Zealand.** Globally, Canada will start up soon having secured ethics approval and France will join later in 2026 or early 2027.

We have reached our first major recruitment milestone, with over 100 patients randomised into the platform (currently 115 in AU and 22 in NZ). In addition, 152 participants in AU and 34 in NZ have been enrolled in the observational registry.

Thank you to all teams across participating sites, as well as those contributing to the various working groups – your ongoing efforts are driving this progress. Please continue to keep the ROADMAP trial front of mind when assessing patients with PJI and help spread awareness among your colleagues. If anyone would like more information, please direct them to our [website](#).

We've built the machine and started it rolling – now our challenge is to grow it and speed it up.

Cheers, Josh



Professor Joshua Davis
Co-ordinating Principal Investigator for ROADMAP



Professor Laurens Manning
Co-ordinating Principal Investigator for ROADMAP

Shout Outs & Milestones

We're thrilled to share that the ROADMAP trial has now surpassed 100 participants recruited.

A special shout-out goes to David Campbell, Renjy Nelson and the Calvary Adelaide team who recruited our 100th participant to the Antibiotic Choice and Duration Domains – a fantastic achievement and a proud moment for the study. To mark the occasion, a small gift will be sent to Calvary Adelaide shortly.

This milestone would not have been possible without the incredible effort across all sites. Thank you for your continued momentum and commitment!



TOP 3 RECRUITING SITES (Platform & Registry):

1. Fiona Stanley Hospital, WA (Australia)
2. John Hunter Hospital, NSW (Australia)
3. Royal Adelaide Hospital, SA (Australia)

FASTEST-GROWING SITES:

- Royal Perth Hospital, WA (Australia)
- Te Toka Tumai Auckland Hospital (New Zealand)

REGIONAL MILESTONES:

- Waitematā (New Zealand) became the first site to enrol a participant in all three treatment domains.
- Ontario (Canada) became the first Province to gain ethics approval, with Kingston gaining the first site-specific approval. Congratulations to Chris, Mazen and the Kingston Hospital team on this achievement.

Platform Enrolment

Correct at 30 April 2026

Domain	Number of Sites Participating	Number of Participants Recruited
Surgical Domain	26 / 27	14
Antibiotic Choice Domain	25 / 27	88
Antibiotic Duration Domain - Part A	26 / 27	15
Antibiotic Duration Domain - Part B	26 / 27	10

Domain enrolment totals may include participants randomised to multiple domains and exclude those still pending assignment; therefore, totals do not represent the overall platform enrolment.


Recruitment by Region

Correct at 30 April 2026

Country	Sites		Participants		Notes
	Active Sites	Sites to be activated	Platform Participants	Registry Participants	
Australia	24	13	115	152	
New Zealand	3	2	22	34	
Canada	0	23	0	0	
France	0	0	0	0	Commencing ethics processes and operational planning
Total	27	38	137	186	

Recruitment over time by Country and Source

Cumulative platform and registry participants to 30 April 2026



OTHER GLOBAL DEVELOPMENTS

- Canada has Health Canada and Ontario ethics approval secured with Kingston being the 1st site approval. Canada has 7 Provinces and 23 sites planning to be involved in ROADMAP at this stage.
- France has commenced operational planning and ethical approval processes with Johan and the team working hard to getting started in Europe. France has a strong collaborative network of clinicians and centres involved with managing patients with PJI.
- A number of other regional teams are awaiting outcomes of submitted grants these include Ireland, Sweden and the USA.

Key Trial Updates

Protocol Updates:

The global ROADMAP Trial Management Group (TMG) is currently conducting the annual review of all protocols and operational documents to ensure they remain up to date and efficient. We are still operating on V2.0 protocols and are compiling any changes for an amendment submission in August 2026.

Isolate Repository:

The Microbiology working group, along with central TMG team members, Jacinta and Hanah, have been working hard to set up operational processes for the collection, transport and storage of isolates collected from ROADMAP participant samples. Required safety approvals have been submitted for review with anticipated approval to be received very soon. This will mean that we can then start receiving and logging isolates in preparation for future studies. The Microbiology Appendix V2.0 has been finalised and will soon be available on the [Resource Documents](#) page following minor updates to streamline site processes. Sites will be notified once it is uploaded.

Antibiotic Choice Domain Update:

Rifampicin supply has been restored, and all Australian sites are able to recruit to Antibiotic Choice Domain if approved to do so. The supply issue slowed recruitment rates in 2025; however, we expect this to improve quickly and for momentum to build.

Team Updates:

Earlier this year we farewelled Jacinta Martin, who had been supporting the trial in the dual role of Data Coordinator and Isolate Repository Coordinator since last year.

We warmly welcome back former team member Jessica Massie as Data Coordinator and our newest recruit, Hanah Hart, who will take on the Isolate Repository role.



Jessica Massie
ROADMAP Data
Coordinator



Hanah Hart
ROADMAP Isolate
Repository Coordinator

It's exciting to see the central team grow alongside the trial!

Meet the rest of the ROADMAP family by visiting the Team Page on our website:
roadmaptrial.com/about/our-team

Stay Connected with ROADMAP

Don't forget to visit the ROADMAP website for key trial information and resources for investigators, site staff, and patients affected by prosthetic joint infections (PJI).

A range of resources are available to support sites, including:

- Videos for patients and investigators
- Protocol and Trial Integrity documents
- FAQ document (version 1.4 now available)
- Region-specific resources via password-protected pages (contact TMG to arrange access)

Visit www.roadmaptrial.com or scan the QR code.



For additional support, contact the central team at TMG@roadmaptrial.com

ROADMAP Resources:
[Approved ROADMAP Documents](#)
[Patient Videos & Conference Recordings](#)

AUSTRALIA

Recruitment in Australia is continuing to build strong momentum, with **24 sites now actively recruiting** – and a bit of friendly competition starting to emerge among our top recruiting sites!


We would like to sincerely thank all sites and teams for your ongoing hard work, collaboration, and commitment to ROADMAP.

We are also delighted to welcome our recently activated sites:
Gold Coast University Hospital and the Mater Hospital Brisbane.

At some sites recruitment has been slower than expected with cross discipline processes needing to be operationalised and new site team members needing to be introduced to ROADMAP. Recruitment has also been impacted by the rifampicin shortage which is now over. Central team coordinator/monitors will be contacting sites to offer support, understand challenges, and work with the site to identify practical solutions.

The Australian Regional TSC recently met to review site performance and explore strategies to support recruitment. Many Investigators at sites have reported that presentations to emergency for PJI have not been at the rates of previous years with reasons for the reduction in cases not being readily identified.

We recently shared a detailed General Communication via email (sent 17 March 2026). One important notification provided was the update to GCP to ICH E6 R3 which is now operational. **All research team members are required to have current GCP certification and will be required to update to R3 training by January 2027.** Refresher training is available via [A-CTEC](#).



Team Australia

MAXIMISING RECRUITMENT OPPORTUNITIES

To support recruitment across all sites, we encourage teams to:

- Keep ROADMAP front of mind by actively raising awareness and using available resources
- Offer both Platform and Registry participation where appropriate
- If a patient declines Platform participation, consider the Registry as an alternative
- Remember that recruitment can occur in multiple care settings, including:
 - o Inpatient wards
 - o Outpatient clinics
 - o Hospital in the Home (HITH) or OPAT services, for patients who meet eligibility criteria

RCPA QAP SURVEY

One of our Microbiology working group members, would like to invite **Senior Microbiology Scientists and Clinical Microbiologists (based in Australia)** to complete a 10-15 minute survey in regard to Prosthetic Joint Infection.

Only one response is required per laboratory.

To ensure data integrity, your RCPA QAP participant number will be recorded to identify duplicate entries. However, all responses will remain anonymous, and identifying information will be removed before analysis.

Survey results will be shared with all participants.

[Start Survey](#)



Congratulations Waitematā
(North Shore) Hospital!

NEW ZEALAND

The ROADMAP trial is gaining great momentum across Aotearoa, with steady progress on recruitment and site activity.

Three New Zealand sites are now fully open and recruiting (Te Toka Tumai (Auckland), Counties Manukau (Middlemore), and Waitematā (North Shore). Tauranga is preparing for a site initiation visit, which will further expand our national footprint and capacity, and Christchurch is close behind.

Recruitment is well underway, with **22 participants enrolled into the ROADMAP platform and 34 participants in the ROADMAP registry nationwide.**

Waitematā became the first site to enrol a participant in all three treatment domains, earning themselves a well-deserved cookie cake to celebrate this milestone!

A warm thank you to all site teams for your continued mahi in supporting participants and keeping the trial moving forward.

In addition, we are pleased to share that a new one-page flyer has recently been approved by the national ethics body (HDEC). This resource is designed to help support recruitment conversations with potential ROADMAP participants. We hope this tool will further strengthen our recruitment efforts across all sites.

Hei konā mai (goodbye for now),



Team New Zealand



Kingston General Hospital,
Ontario Canada

CANADA

Exciting progress from our Canadian team!

We're pleased to share that provincial approval in Ontario for the study sponsor has now been secured – marking a major milestone and the first official step toward launching ROADMAP in Canada.

With this approval in place, the team is now moving full steam ahead into the next phase. Ethics submissions at individual sites will begin in earnest across the province, alongside approvals the process of establishing site agreements is also occurring. Kingston General Hospital is the 1st site obtaining site approval.

Canada is planning to involve all Provinces expressing interest in ROADMAP with 7 having done so to date. At this stage **23 sites have been identified as being potential ROADMAP sites.** All this momentum brings us significantly closer to opening sites and welcoming Canadian participants into the ROADMAP study.

We look forward to sharing further updates as things continue to progress across the region.



Team Canada

Upcoming Committee & Working Group Meetings (May-July)

The following ROADMAP Committee and Working Group meetings are scheduled over the coming months. Please check your calendars for these dates and look out for invitations, agendas and reminders.

Surgical Working Group: 13 May, 5pm AEST

Data Safety & Monitoring Committee (DSMC): 15 May 2026, 9:30am AEST

Global Trial Steering Committee (GTSC): 18 May 2026, 6pm AEST

ROADMAP Surgeons Town Hall (Aus & NZ only): 3 June, 7pm AEST

Global Trial Steering Committee (GTSC): 16 July 2026, 9:30am AEST

Publications & Highlights



ESCMID Global 2026

Josh Davis caught up with Johan Courjon, the French ROADMAP lead investigator, at the ESCMID Global meeting in Munich in April.

It was a great conference, which gets bigger every year (over 18,000 delegates), but there was not a lot of bone and joint infection content – something we hope to remedy next year!

Podcast Spotlight

Keen to learn more about innovative trial design? Check out *In the Interim*, a podcast from the Berry Group in Texas. **Episode #48 focuses on another orthopaedic adaptive platform trial (in hip).**

[Listen Here](#)

A more recent episode features Professors Joshua Davis and Steven Tong, discussing the SNAP trial. Visit www.berryconsultants.com/podcast for more.



Do you have something interesting to share in a future newsletter?

Please get in touch if you'd like to share a member or team profile, talk about a past or upcoming event, special achievement or interest. We'd love to hear from you!

ROADMAP Trial Management Group (TMG)

Chief investigators: Professor Joshua Davis & Professor Laurens Manning

Global Clinical Trial Manager: Dr Marline Squance

Data Coordinator: Jessica Massie

Isolate Repository Coordinator: Hanah Hart

Trial Coordinators/Monitors: Mia Di Virgilio & Alana Di Giacomo

Administrative Assistant: Sandy Isles



Email: TMG@roadmaptrial.com

Website: www.roadmaptrial.com